Park, Yae Won;
Vollmuth, Philipp;
Foltyn‐Dumitru, Martha;
Sahm, Felix;
Ahn, Sung Soo;
Chang, Jong Hee;
Kim, Se Hoon
The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 2—Summary of Imaging Findings on Pediatric‐Type Diffuse High‐Grade Gliomas, Pediatric‐Type Diffuse Low‐Grade Gliomas, and Circumscribed Astrocytic Gliomas
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 2—Summary of Imaging Findings on Pediatric‐Type Diffuse High‐Grade Gliomas, Pediatric‐Type Diffuse Low‐Grade Gliomas, and Circumscribed Astrocytic Gliomas
Beteiligte:
Park, Yae Won;
Vollmuth, Philipp;
Foltyn‐Dumitru, Martha;
Sahm, Felix;
Ahn, Sung Soo;
Chang, Jong Hee;
Kim, Se Hoon
Erschienen:
Wiley, 2023
Erschienen in:Journal of Magnetic Resonance Imaging
Sprache:
Englisch
DOI:
10.1002/jmri.28740
ISSN:
1522-2586;
1053-1807
Entstehung:
Anmerkungen:
Beschreibung:
<jats:sec><jats:label /><jats:p>The fifth edition of the World Health Organization (WHO) classification of central nervous system tumors published in 2021 advances the role of molecular diagnostics in the classification of gliomas by emphasizing integrated diagnoses based on histopathology and molecular information and grouping tumors based on genetic alterations. This Part 2 review focuses on the molecular diagnostics and imaging findings of pediatric‐type diffuse high‐grade gliomas, pediatric‐type diffuse low‐grade gliomas, and circumscribed astrocytic gliomas. Each tumor type in pediatric‐type diffuse high‐grade glioma mostly harbors a distinct molecular marker. On the other hand, in pediatric‐type diffuse low‐grade gliomas and circumscribed astrocytic gliomas, molecular diagnostics may be extremely complicated at a glance in the 2021 WHO classification. It is crucial for radiologists to understand the molecular diagnostics and imaging findings and leverage the knowledge in clinical practice.</jats:p></jats:sec><jats:sec><jats:title>Evidence Level</jats:title><jats:p>3</jats:p></jats:sec><jats:sec><jats:title>Technical Efficacy</jats:title><jats:p>Stage 3.</jats:p></jats:sec>